A number of other equities analysts have also recently issued reports on the company. Leerink Swann restated a buy rating on shares of Eli Lilly and in a report on Sunday, June 26th. Argus increased their price target on Eli Lilly and from $90.00 to $95.00 and gave the stock a buy rating in a report on Tuesday, August 2nd. Zacks Investment Research upgraded Eli Lilly and from a hold rating to a buy rating and set a $93.00 price target on the stock in a report on Friday, July 29th. Citigroup Inc. restated a buy rating on shares of Eli Lilly and in a report on Wednesday, August 3rd. Finally, JPMorgan Chase & Co. upgraded Eli Lilly and from a neutral rating to an overweight rating and increased their price target for the stock from $92.00 to $95.00 in a report on Thursday, September 8th. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $97.16.
Eli Lilly and (NYSE:LLY) opened at 81.47 on Monday. The company’s 50-day moving average is $79.37 and its 200-day moving average is $77.41. The firm has a market capitalization of $86.17 billion, a P/E ratio of 35.12 and a beta of 0.17. Eli Lilly and has a one year low of $67.88 and a one year high of $88.16.
Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.86. The business earned $5.40 billion during the quarter, compared to the consensus estimate of $5.14 billion. Eli Lilly and had a net margin of 11.97% and a return on equity of 23.99%. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.90 EPS. Equities analysts forecast that Eli Lilly and will post $3.59 earnings per share for the current fiscal year.
In related news, insider Donald A. Zakrowski sold 1,213 shares of Eli Lilly and stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $83.16, for a total value of $100,873.08. Following the completion of the sale, the insider now owns 1,300 shares of the company’s stock, valued at approximately $108,108. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $79.54, for a total value of $16,703,400.00. Following the completion of the sale, the insider now directly owns 126,220,804 shares of the company’s stock, valued at approximately $10,039,602,750.16. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.
A number of large investors have recently made changes to their positions in the company. Iowa State Bank purchased a new stake in shares of Eli Lilly and during the second quarter valued at $104,000. PineBridge Investments L.P. increased its position in shares of Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock valued at $108,000 after buying an additional 920 shares in the last quarter. Cribstone Capital Management LLC bought a new position in shares of Eli Lilly and during the second quarter valued at approximately $117,000. Coconut Grove Bank increased its position in shares of Eli Lilly and by 3.3% in the second quarter. Coconut Grove Bank now owns 1,550 shares of the company’s stock valued at $122,000 after buying an additional 50 shares in the last quarter. Finally, Physicians Financial Services Inc. increased its position in shares of Eli Lilly and by 11.2% in the second quarter. Physicians Financial Services Inc. now owns 1,638 shares of the company’s stock valued at $129,000 after buying an additional 165 shares in the last quarter. 74.96% of the stock is owned by institutional investors.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.